Noir Immuno BioTech <4893> announced on the 20th that it has been newly selected as a borrowed stock on the Tokyo Stock Exchange Growth Market.
The company is an academia-based biotech that is working on the practical application of next-generation cancer immunotherapy for solid cancers with PRIME CAR-T cells equipped with PRIME technology, an innovative technology unique to the company that enhances the therapeutic effect of immune cell therapy.
The selection date is December 23, 2024 (Monday), and it will be implemented from the trades of that day.
This selection as a borrowed stock is expected to promote the liquidity and supply-demand relationship of the company's stocks, contributing to the activation of trading and the formation of fair prices.